KRAS(G12C) Coupled Nucleotide Exchange Assay Kit (Discontinued)
The KRAS(G12C) Coupled Nucleotide Exchange Assay Kit is designed for screening and profiling of KRAS(G12C) antagonists/inhibitors by monitoring the binding of an effector protein (i.e. Ras binding domain of Raf1, RBD-cRaf) to KRAS(G12C). The KRAS(G12C) Coupled Nucleotide Exchange Assay Kit comes in a convenient 384-well format, with enough purified recombinant GDP-loaded KRAS(G12C) Isoform A, GTP, exchange factor SOS1, an effector protein RBD-cRAF, assay buffer and additives for 400 reactions. With this kit, a few simple steps on a microtiter plate are required for nucleotide exchange detection. First, a sample containing GDP-loaded KRAS(G12C) is incubated with SOS1 and GTP for the nucleotide exchange. Next, RBD-cRAF is added and incubated for the effector-RAS binding. Then, acceptor and donor beads are added and incubated for detection followed by reading the Alpha-counts.
SOS1 is a guanine nucleotide exchange factor that facilitates the exchange of GDP for GTP. GDP-loaded KRAS(G12C) is in an inactive state, and does not interact with the Ras-binding domain (RBD) of cRAF. SOS1 assists in the release GDP from KRAS(G12C) so that GTP can occupy the nucleotide binding pocket. This results in a conformational change in KRAS(G12C) that permits binding of RBD-cRAF to KRAS(G12C). The KRAS(G12C) Coupled Nucleotide Exchange Assay Kit utilizes GST-tagged RBD-cRAF and His-tagged KRAS (G12C) to assay binding of KRAS(G12C) to RBD-cRAF in the Alpha assay. Glutathione acceptor and Ni chelate donor beads are brought into proximal range by the binding of KRAS(G12C) and RBD-cRAF, enabling the energy transfer from the donor to acceptor beads after laser excitation.
AlphaLISA® Glutathione acceptor beads, 5 mg/ml (PerkinElmer #AL109C)
AlphaScreen® Nickel Chelate donor beads, 5 mg/ml (PerkinElmer #AS101D)
Optiplate -384 (PerkinElmer #6007290)
AlphaScreen® microplate reader
Adjustable micropipettor and sterile tips
Catalog Number |
Name | Amount | Storage |
100640 | GDP loaded KRAS(G12C), Isoform A, His-tag* | 10 μg | -80°C |
100753 | SOS1, FLAG-Tag, Avi-Tag, Biotin-Labeled* | 2 x 100 µg | -80°C |
100519 | RBD-cRAF, GST-tag | 5 µg | -80°C |
79861-2 | GTP (10 mM) | 0.5 ml | -20°C |
78351 | RBD-RAS Binding Buffer | 6 ml | 4°C |
79311 | 3x Immuno Buffer 1 | 4 ml | -20°C |
*The concentration of the protein is lot-specific and will be indicated on the tube.
It is well established that RAS mutations are responsible for more than 30% of human cancers. KRAS(G12C) is one of the KRAS mutations that is found frequently in lung and colon cancers. The G12C mutation favors the activated (GTP-bound) state of KRAS, amplifying signaling pathways that lead to oncogenesis. Recent studies have led to the discovery of a small molecule called AMG510 (Amgen) that locks KRAS conformation in the GDP-bound (inactive) state, thereby blocking KRAS(G12C)-mediated signaling pathway. Compounds that affect the nucleotide exchange (GDP to GTP) reaction could lead to a novel approach leading to the inhibition of tumor cell growth in KRAS(G12C) driven tumors.
1. Canon, J., et al. Nature 2019; 575:217-223.
2. Hillig, R.C., et al. 2019. PNAS USA 116 (7): 2551-2560